User Login
|
Create Account
|
Contact Us
Facebook
Instagram
X
LinkedIn
TikTok
Home
Browse By Tumor Type
Upcoming Events
About Us
Subscribe
CME Post-Tests
Home
We've determined that you are accessing this site using a mobile device. Please select which version of the site you would like to browse.
RTP On Demand: Current Controversies and Emerging Data Sets in Follicular Lymphoma and Chronic Lymphocytic Leukemia
Home
CME test
CME information and faculty disclosures
Select publications
Novel agents in FL and CLL: BTK inhibitors
10:01 minutes.
NEXT VIDEO:
Targeted therapies in lymphomas and CLL: BTK, Syk and PI3Kδ inhibitors
Related videos:
BRIGHT and StiL NHL1-2003 studies of bendamustine/rituximab versus rituximab/chemotherapy in NHL
Rituximab schedule and maintenance in FL
Rituximab combined with lenalidomide (R squared) in untreated lymphoma
Type II anti-CD20 monoclonal antibody obinutuzumab in CLL
Targeted therapies in lymphomas and CLL: BTK, Syk and PI3Kδ inhibitors
Case 1: 59-year-old woman with Stage IE, Grade 3A FL
Case 2: 48-year-old woman diagnosed 10 years ago with FL
Case 3: 62-year-old man with Grade 1 FL and Stage IIA colon adenocarcinoma
Case 4: 60-year-old man with asymptomatic progression of CLL